Pacira BioSciences [PCRX] vs BioCryst [BCRX] Detailed Stock Comparison
Pacira BioSciences
NASDAQ
Loading...
BioCryst
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Pacira BioSciences wins in 8 metrics, BioCryst wins in 11 metrics, with 0 ties. BioCryst appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pacira BioSciences | BioCryst | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.14 | -19.94 | BioCryst |
| Price-to-Book Ratio | 1.50 | -4.26 | BioCryst |
| Debt-to-Equity Ratio | 83.32 | -1.75 | BioCryst |
| PEG Ratio | -0.10 | 0.15 | Pacira BioSciences |
| EV/EBITDA | 8.37 | 38.25 | Pacira BioSciences |
| Profit Margin (TTM) | -18.06% | -6.41% | BioCryst |
| Operating Margin (TTM) | 5.04% | 18.23% | BioCryst |
| EBITDA Margin (TTM) | 5.04% | 18.23% | BioCryst |
| Return on Equity | -15.57% | 18.68% | BioCryst |
| Return on Assets (TTM) | 2.69% | 7.46% | BioCryst |
| Free Cash Flow (TTM) | $178.75M | $-53.14M | Pacira BioSciences |
| 1-Year Return | 82.10% | 5.68% | Pacira BioSciences |
| Price-to-Sales Ratio (TTM) | 1.62 | 3.16 | Pacira BioSciences |
| Enterprise Value | $1.33B | $2.24B | BioCryst |
| EV/Revenue Ratio | 1.88 | 4.01 | Pacira BioSciences |
| Gross Profit Margin (TTM) | 77.43% | 98.29% | BioCryst |
| Revenue per Share (TTM) | $15 | $3 | Pacira BioSciences |
| Earnings per Share (Diluted) | $-2.75 | $-0.18 | BioCryst |
| Beta (Stock Volatility) | 0.48 | 1.10 | Pacira BioSciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Pacira BioSciences vs BioCryst Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pacira BioSciences | 1.77% | 4.28% | 15.20% | -0.88% | 2.34% | 40.97% |
| BioCryst | 2.15% | 2.27% | -1.04% | -17.61% | 3.26% | 9.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pacira BioSciences | 82.10% | -52.20% | -57.50% | -56.08% | 267.57% | 267.57% |
| BioCryst | 5.68% | -39.97% | 115.62% | -25.04% | 77.59% | -0.58% |
Performance & Financial Health Analysis: Pacira BioSciences vs BioCryst
| Metric | PCRX | BCRX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.14B | $1.76B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 724,020 | 2,267,540 |
| 90 Day Avg. Volume | 734,633 | 3,253,080 |
| Last Close | $25.84 | $8.56 |
| 52 Week Range | $12.61 - $27.64 | $6.02 - $11.31 |
| % from 52W High | -6.51% | -24.31% |
| All-Time High | $121.95 (Feb 23, 2015) | $37.25 (Mar 06, 2000) |
| % from All-Time High | -78.81% | -77.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.49% |
| Quarterly Earnings Growth | 0.02% | 0.49% |
| Financial Health | ||
| Profit Margin (TTM) | -0.18% | -0.06% |
| Operating Margin (TTM) | 0.05% | 0.18% |
| Return on Equity (TTM) | -0.16% | 0.19% |
| Debt to Equity (MRQ) | 83.32 | -1.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $16.88 | $-2.01 |
| Cash per Share (MRQ) | $9.92 | $1.24 |
| Operating Cash Flow (TTM) | $134.52M | $16.82M |
| Levered Free Cash Flow (TTM) | $108.49M | $53.98M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Pacira BioSciences vs BioCryst
| Metric | PCRX | BCRX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.14 | -19.94 |
| Forward P/E | 8.38 | -209.50 |
| PEG Ratio | -0.10 | 0.15 |
| Price to Sales (TTM) | 1.62 | 3.16 |
| Price to Book (MRQ) | 1.50 | -4.26 |
| Market Capitalization | ||
| Market Capitalization | $1.14B | $1.76B |
| Enterprise Value | $1.33B | $2.24B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.88 | 4.01 |
| Enterprise to EBITDA | 8.37 | 38.25 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 1.10 |
| Book Value per Share (MRQ) | $16.88 | $-2.01 |
Financial Statements Comparison: Pacira BioSciences vs BioCryst
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PCRX | BCRX |
|---|---|---|
| Revenue/Sales | $168.92M | $145.53M |
| Cost of Goods Sold | $34.31M | $4.57M |
| Gross Profit | $134.62M | $140.97M |
| Research & Development | $25.34M | $37.27M |
| Operating Income (EBIT) | $8.18M | $21.23M |
| EBITDA | $39.80M | $24.58M |
| Pre-Tax Income | $8.71M | $758,000 |
| Income Tax | $3.89M | $726,000 |
| Net Income (Profit) | $4.81M | $32,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PCRX | BCRX |
|---|---|---|
| Cash & Equivalents | $283.61M | $105.19M |
| Total Current Assets | $759.96M | $409.98M |
| Total Current Liabilities | $314.73M | $139.86M |
| Long-Term Debt | $424.97M | $792.12M |
| Total Shareholders Equity | $798.54M | $-451.93M |
| Retained Earnings | $-201.54M | $-1.77B |
| Property, Plant & Equipment | $48.73M | $19.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PCRX | BCRX |
|---|---|---|
| Operating Cash Flow | $37.87M | $21.14M |
| Capital Expenditures | $-8.55M | $-143,000 |
| Free Cash Flow | $26.91M | $-27.66M |
| Debt Repayment | $-2.81M | $-516,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PCRX | BCRX |
|---|---|---|
| Shares Short | 5.69M | 25.88M |
| Short Ratio | 9.86 | 8.05 |
| Short % of Float | 0.18% | 0.12% |
| Average Daily Volume (10 Day) | 724,020 | 2,267,540 |
| Average Daily Volume (90 Day) | 734,633 | 3,253,080 |
| Shares Outstanding | 46.24M | 208.54M |
| Float Shares | 39.83M | 207.69M |
| % Held by Insiders | 0.02% | 0.01% |
| % Held by Institutions | 1.16% | 0.95% |
Dividend Analysis & Yield Comparison: Pacira BioSciences vs BioCryst
| Metric | PCRX | BCRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |